跳至主要内容
临床试验/JPRN-UMIN000014435
JPRN-UMIN000014435已完成1 期

The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides containing helper epitopes for malignant tumor. - The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides for malignant tumor.

Medical Corporation Isokai Seren Clinic Tokyo0 个研究点目标入组 10 人开始时间: 2014年6月30日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • The patients have been (1) Diagnosed or suspected of myelodysplastic syndrome (MDS). (2) Suspected of other severe clinical conditions or abnormal laboratory values. (3) Diagnosed or suspected of a mental disorder or mental symptoms. (4) Suspected of immunodeficiency and/or infection. Other exclusion criteria are as follows: (5) Pregnant, lactating or suspected of pregnancy. (6) Female patient rejecting to give consent to contraception during the therapy and for 70 days after the completion of the final administration. (7) Taking in adrenocortical steroid (at the equivalent of 10mg predonine or prednisolone per day). (8) Unsuitable for the therapy.

研究者

发起方
Medical Corporation Isokai Seren Clinic Tokyo

相似试验